- Home
- SGC vs CYBN Comparison
SGC vs CYBN Comparison
Compare SGC & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- CYBN
- Stock Information
- Founded
- SGC 1920
- CYBN 2019
- Country
- SGC United States
- CYBN Canada
- Employees
- SGC N/A
- CYBN N/A
- Industry
- SGC Apparel
- CYBN Pharmaceuticals and Biotechnology
- Sector
- SGC Consumer Discretionary
- CYBN Health Care
- Exchange
- SGC Nasdaq
- CYBN Nasdaq
- Market Cap
- SGC 215.7M
- CYBN 176.5M
- IPO Year
- SGC N/A
- CYBN N/A
- Fundamental
- Price
- SGC N/A
- CYBN $6.15
- Analyst Decision
- SGC Strong Buy
- CYBN Strong Buy
- Analyst Count
- SGC 3
- CYBN 3
- Target Price
- SGC $17.33
- CYBN $85.00
- AVG Volume (30 Days)
- SGC 40.8K
- CYBN 703.6K
- Earning Date
- SGC 11-05-2025
- CYBN 11-12-2025
- Dividend Yield
- SGC 5.54%
- CYBN N/A
- EPS Growth
- SGC N/A
- CYBN N/A
- EPS
- SGC 0.52
- CYBN N/A
- Revenue
- SGC $576,240,000.00
- CYBN N/A
- Revenue This Year
- SGC $1.76
- CYBN N/A
- Revenue Next Year
- SGC $3.37
- CYBN N/A
- P/E Ratio
- SGC $19.35
- CYBN N/A
- Revenue Growth
- SGC 4.03
- CYBN N/A
- 52 Week Low
- SGC $9.11
- CYBN $4.81
- 52 Week High
- SGC $18.48
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- SGC 33.58
- CYBN 45.75
- Support Level
- SGC $10.35
- CYBN $5.72
- Resistance Level
- SGC $10.95
- CYBN $6.63
- Average True Range (ATR)
- SGC 0.46
- CYBN 0.34
- MACD
- SGC -0.13
- CYBN 0.07
- Stochastic Oscillator
- SGC 9.95
- CYBN 38.45
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.